Malignant Neoplasm Clinical Trials

41 recruiting

Malignant Neoplasm Trials at a Glance

164 actively recruiting trials for malignant neoplasm are listed on ClinicalTrialsFinder across 6 cities in 48 countries. The largest study group is Phase 2 with 52 trials, with the heaviest enrollment activity in Houston, Los Angeles, and New York. Lead sponsors running malignant neoplasm studies include M.D. Anderson Cancer Center, Mayo Clinic, and City of Hope Medical Center.

Browse malignant neoplasm trials by phase

Treatments under study

About Malignant Neoplasm Clinical Trials

Looking for clinical trials for Malignant Neoplasm? There are currently 41 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignant Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignant Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 164 trials

Recruiting

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Bladder CancerKidney CancerRenal Cancer+2 more
National Cancer Institute (NCI)5,950 enrolled1 locationNCT00026884
Recruiting
Phase 2

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Malignant Neoplasm
Merck Sharp & Dohme LLC130 enrolled21 locationsNCT07252739
Recruiting
Not Applicable

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

Breast CancerBreast CarcinomaCancer of the Breast+1 more
National Cancer Institute (NCI)175 enrolled1 locationNCT07067138
Recruiting
Phase 1Phase 2

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Stage IVB Prostate Cancer AJCC v8Metastatic Malignant Neoplasm in the BoneMetastatic Castration-Resistant Prostate Carcinoma+1 more
National Cancer Institute (NCI)90 enrolled32 locationsNCT04071236
Recruiting
Phase 1Phase 2

A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

LymphomaMalignant NeoplasmCarcinoma, Merkel Cell
Merck Sharp & Dohme LLC20 enrolled3 locationsNCT07302347
Recruiting
Phase 1Phase 2

NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

Malignant NeoplasmMalignant Neoplasm of Brain
Novelwise Pharmaceutical Corporation79 enrolled4 locationsNCT06012695
Recruiting

Norris ORIEN Total Cancer Care

Cancer RiskMalignant Neoplasm
University of Southern California10,000 enrolled1 locationNCT02970045
Recruiting
Phase 2

Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer

Metastatic Malignant Neoplasm
Roswell Park Cancer Institute1,500 enrolled3 locationsNCT04068649
Recruiting
Phase 3

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

Stage IV Lung Cancer AJCC v8Metastatic Malignant Neoplasm in the BrainMetastatic Lung Small Cell Carcinoma+1 more
NRG Oncology200 enrolled227 locationsNCT04804644
Recruiting
Phase 2

Intraoperative Tumor Margin Identification With ICG Dye Imaging

Malignant NeoplasmBenign Neoplasm
Massachusetts General Hospital100 enrolled1 locationNCT04752137
Recruiting
Phase 1Phase 2

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Malignant Neoplasm
Tyligand Pharmaceuticals (Suzhou) Limited440 enrolled19 locationsNCT06385925
Recruiting
Phase 1Phase 2

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdvanced Malignant Neoplasm+4 more
Kura Oncology, Inc.263 enrolled56 locationsNCT04067336
Recruiting

Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

Malignant Neoplasm
Rutgers, The State University of New Jersey1,100 enrolled11 locationsNCT02688517
Recruiting

Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer

Carcinoma of Unknown PrimaryMetastatic Malignant Neoplasm in the Uterine CervixClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+28 more
M.D. Anderson Cancer Center471 enrolled1 locationNCT03010150
Recruiting

Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer

Invasive Breast CarcinomaInflammatory Breast CarcinomaSecond Primary Malignant Neoplasm
M.D. Anderson Cancer Center1,200 enrolled10 locationsNCT00477100
Recruiting
Phase 1

Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

Malignant Neoplasms of Respiratory and Intrathoracic OrgansSquamous Cell Carcinoma of the Larynx
M.D. Anderson Cancer Center11 enrolled1 locationNCT03114462
Recruiting
Not Applicable

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Metastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Renal Cell Carcinoma+15 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT04693377
Recruiting
Phase 1

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

Malignant Neoplasm
Merck Sharp & Dohme LLC250 enrolled15 locationsNCT07247110
Recruiting
Phase 2

SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial

Metastatic Malignant Solid NeoplasmMetastatic Malignant Neoplasm in the Brain
Mayo Clinic90 enrolled7 locationsNCT05222620
Recruiting
Phase 1Phase 2

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

Malignant Neoplasm
Merck Sharp & Dohme LLC50 enrolled59 locationsNCT06941272